Previstage(TM) GCC to be presented at ASCO GI

    Ticker Symbol: CUR

    QUEBEC CITY, Jan. 12 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life
sciences company commercializing high-value cancer diagnostic tests and
delivering lab services, and its wholly-owned subsidiary, DiagnoCure Oncology
Laboratories based in West Chester, PA, near Philadelphia, will exhibit at the
American Society of Clinical Oncology The Gastrointestinal Cancers Symposium
(ASCO GI) beginning January 15th in San Francisco, California. The Company is
also sponsoring an Independent Satellite Symposium to be conducted adjunct to
ASCO GI on January 14th, during which molecular markers for colorectal cancer
will be discussed.
    DiagnoCure will take this opportunity to meet surgeons, oncologists,
radiologists and other clinical specialists who focus on treating patients
with colorectal and other cancers of the gastrointestinal tract, and increase
their awareness about its Previstage(TM) GCC Colorectal Cancer Staging Test,
launched last August in the United States.
    In particular, DiagnoCure has provided an unrestricted educational grant
for the Independent Satellite Symposium, "Molecular Markers and Prognosis of
Patients with Colorectal Cancer". Three members of DiagnoCure's Strategic
Advisory Board, Dr. Edith P. Mitchel (Thomas Jefferson University), Dr.
Stanley Hamilton (University of Texas M.D. Anderson Cancer Center) and Dr.
Daniel Sargent (Mayo Clinic), will be speaking about patients with colorectal
cancer, including a review of the value of colorectal cancer staging. Medical
Education Resources, Inc., an ACCME accredited provider, designates this
presentation as a creditable educational activity.

    OneMedForum Annual Meeting

    Also, on January 14th, the Company will be exhibiting and Mr. John
Schafer, President and CEO, will be presenting a company overview during the
2nd Annual OneMedForum, at 3:30 p.m. (ET), at the Sir Francis Drake Hotel, in
San Francisco (CA).
    The financial forum will bring together promising emerging healthcare and
life science companies with strategic and venture investors focused on new
technologies, emerging and micro cap public companies.

    About Previstage(TM) GCC

    Every year in North America, 174,000 people are diagnosed with colorectal
cancer, and 142,000 colorectal cancer surgeries are performed. Staging a
patient with colorectal cancer is crucial because it determines the patient's
course of treatment after the surgery. Current standard of care requires that
pathologists microscopically examine a thin slice of tissue from each of the
lymph nodes harvested during the patient's surgery to see if cancer has
spread. Currently, up to 30 percent of patients with no pathologically
positive lymph nodes (stage I and II cancers) later develop recurrent disease,
presumably through occult metastases that have escaped detection. Most of
these patients do not receive additional therapies such as chemotherapy. With
a detection capacity that is close to 100,000 more sensitive than microscopic
methods, Previstage(TM) GCC provides clinicians with significantly more
accurate information for staging a patient with colorectal cancer that will
increase their confidence in making critical treatment decisions.
    Clinical study data supports the potential for the GCC test to improve
the current staging of colorectal patients. The National Cancer Institute
sponsored a five-year prospective clinical trial of GCC testing in colorectal
cancer patients. This study has been recently completed and the Company's
collaborators at Thomas Jefferson University are presenting the results at
major medical conferences throughout the year. The Previstage(TM) GCC
Colorectal Cancer Staging Test is a laboratory-developed test and its
performance characteristics have been determined by DiagnoCure Oncology

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services that
increase clinician and patient confidence in making critical treatment
decisions. In 2008, DiagnoCure Oncology Laboratories, a subsidiary of
DiagnoCure Inc., launched the Previstage(TM) GCC Colorectal Cancer Staging
Test, the first GCC based molecular test for the management of colorectal
cancer. The Company also has a strategic alliance with GenProbe (NASDAQ:   GPRO)
for the development and commercialization of a second-generation prostate
cancer test using PCA3, DiagnoCure's proprietary molecular marker. This test
is also available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) from GenProbe, in Europe as the CE-marked PROGENSA(TM) PCA3 in
vitro assay, and in Canada. For more information, visit

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.
    %SEDAR: 00003671EF

For further information:

For further information: Investors: J.F. Bureau, CFA, Sr. Vice President
and CFO, DiagnoCure Inc., (418) 527-6100; Media: Isabelle Taschereau,
Associate Director, Corporate Affairs, DiagnoCure Inc., (418) 527-6100,

Organization Profile

DiagnoCure Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890